奈达铂或顺铂分别联合紫杉醇同步放疗用于中晚期宫颈癌的疗效比较

发布时间：2018-06-07 16:38

本文选题：宫颈癌 + 同步放化疗　；参考：《中国药房》2017年03期

【摘要】：目的:观察奈达铂或顺铂分别联合紫杉醇同步放疗用于中晚期宫颈癌的临床疗效和安全性。方法:120例中晚期宫颈癌患者随机分为观察组(60例)和对照组(60例)。观察组患者给予注射用奈达铂20 mg/m~2静脉滴注+紫杉醇注射液35 mg/m~2静脉滴注,每周1次;对照组患者给予注射用顺铂20 mg/m~2静脉滴注+紫杉醇注射液35 mg/m~2静脉滴注,每周1次。两组患者均予以同步放射治疗,先予以全盆腔放射治疗1.8~2.0 Gy/次,每日1次,每周5次,然后进行盆腔视野外放射治疗1.8~2.0 Gy/次,每日1次,每周4次。1周为1个疗程,两组均治疗6周。观察两组患者近期疗效、2年生存率、2年局部控制率和不良反应发生率。结果:治疗后,观察组患者有效率、2年生存率、2年局部控制率显著高于对照组,骨髓抑制发生率显著低于对照组,差异均有统计学意义(P0.05);两组患者消化道反应、肝肾功能损害、脱发以及周围神经炎等不良反应发生率比较,差异无统计学意义(P0.05)。结论:奈达铂联合紫杉醇同步放化疗用于中晚期宫颈癌的近期疗效、2年生存率、2年局部控制率优于顺铂联合紫杉醇,安全性方面两者相当,但前者较少发生骨髓抑制。
[Abstract]:Aim: to observe the efficacy and safety of neidplatin or cisplatin combined with paclitaxel in the treatment of advanced cervical cancer. Methods 120 patients with advanced cervical cancer were randomly divided into observation group (n = 60) and control group (n = 60). The patients in the observation group were given paclitaxel injection for 20 mg/m~2, once a week, while the patients in the control group were given cisplatin 20 mg/m~2 intravenously for 35 mg/m~2, once a week. All patients in both groups were given concurrent radiotherapy. The patients were given total pelvic radiotherapy for 1. 8 Gy/, once a day, 5 times a week, and then for 1. 8 Gy/ per day, 4 times a week as a course of treatment. Both groups were treated for 6 weeks. The short-term curative effect, 2-year survival rate, 2-year local control rate and adverse reaction rate were observed. Results: after treatment, the effective rate, 2-year survival rate, 2-year local control rate and bone marrow suppression rate in the observation group were significantly higher than those in the control group, and the difference was statistically significant (P 0.05). There was no significant difference in the incidence of adverse reactions such as alopecia and peripheral neuritis (P 0.05). Conclusion: Nedaplatin combined with paclitaxel combined with radiotherapy and chemotherapy is effective in the treatment of advanced cervical cancer. The 2-year survival rate and 2-year local control rate are superior to those of cisplatin combined with paclitaxel, but the former has less bone marrow suppression.
【作者单位】：南京医科大学附属淮安第一医院;
【分类号】：R737.33

【相似文献】